Psoriasis
Conditions
Interventions
Sponsors
Guangdong Provincial Hospital of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 years, both male and female; 2. The patients with PASI >= 10 or BSA >= 10, met the diagnostic criteria of severe psoriasis; 3. Patients who meet the indications of biological agents Ixekizumab and have no history of inflammatory bowel disease (IBD); 4. Patients who sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women, or those who plan pregnancy during the study period. 2. Patients with Self-Rating Anxiety Scale (SAS) score > 50 or Self-Rating Depression Scale (SDS) standard score > 53, or with other mental disorders. 3. Patients with severe primary diseases such as respiratory system and circulatory system that cannot be controlled by conventional medication; patients with severe infection, tuberculosis, hepatitis and other infectious history, lymphocyte proliferation, hematopoietic system abnormalities, tumor; patients with severe water, electrolyte and acid-base balance disorder; patients with primary or secondary immune deficiency and hypersensitivity. Or clinical test indicators are one of the following cases: alanine aminotransferase or glutamic oxaloacetic transaminase increase > 3 x ULN; creatinine > 1.5 x ULN; serological test of human immunodeficiency virus (HIV) is positive; any main indicators of blood test is below the lower limit of normal; or other abnormal laboratory tests. 4. Patients who are known to be allergic to the medication and its related ingredients used in this study and those with related medication ingredients. 5. Those who are participating in other medication clinical trials or have participated in other clinical trials within 4 weeks. 6. Those who used Traditional Chinese Medicine or Chinese herbal products or topical therapy (antibiotics, external corticosteroids, vitamin D3 analogues, calcineurin inhibitors, keratolytics, etc.) within 2 weeks; those who had used oral systemic therapies (methotrexate, ciclosporin A, acitretin, fumarates, etc.) or ultraviolet treatment within 4 weeks; those who had received biological agents within 5 half-life periods (17.5 days of Etanercept, 50 days of Infliximab, 70 days of Adalimumab, 105 days of Ustekinumab, 135 days of Secukinumab, etc.). 7. Patients are assessed as unsuitable for inclusion by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relapse rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to relapse;The improvement in PASI (Psoriasis Area and Severity Index) score;The proportion of patients who achieve at least 75% improvement in PASI score;The proportion of patients who achieve at least 90% improvement in PASI score;Physician's global assessment (PGA) score;Pruritus Scores on the Visual Analogue Scale;Body Surface Area;Dermatology Life Quality Index (DLQI);Skindex16;Patients' attitudes, expectation and experience; | — |
Countries
China
Contacts
Public ContactLu Chuanjian
Guangdong Provincial Hospital of Chinese Medicine
Outcome results
None listed